Status:

COMPLETED

A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

Lead Sponsor:

Eli Lilly and Company

Conditions:

Spondyloarthritis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).

Eligibility Criteria

Inclusion

  • Have an established diagnosis of radiographic axial spondyloarthritis (r-xSpA) with sacroiliitis defined radiographically according to the modified New York criteria.
  • Participants have a history of back pain ≥3 months with age at onset \<45 years.
  • Biologic naïve or have had prior treatment with 1 tumor necrosis factor (TNF) inhibitor.
  • Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.
  • Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

Exclusion

  • Have total ankylosis of the spine.
  • Have recently received a live vaccine within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.
  • Have an ongoing or serious infection within the last 12 weeks.
  • Have a compromised immune system.
  • Have any other serious and/or uncontrolled diseases.
  • Have either a current diagnosis or a recent history of malignant disease.
  • Have had major surgery within 8 weeks of baseline, or will require surgery during the study.
  • Are pregnant or breastfeeding.

Key Trial Info

Start Date :

April 10 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 17 2022

Estimated Enrollment :

147 Patients enrolled

Trial Details

Trial ID

NCT04285229

Start Date

April 10 2020

End Date

March 17 2022

Last Update

April 14 2023

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

Afflilated Hospital of Bengbu Medical College

Bengbu, Anhui, China, 233004

2

Anhui Provincial Hospital

Hefei, Anhui, China, 230001

3

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China, 510120

4

Shenzhen People's Hospital

Shenzhen, Guangdong, China, 518020

A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis | DecenTrialz